China Pharma (CPHI) Competitors $1.50 -0.06 (-4.06%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.54 +0.04 (+2.57%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CPHI vs. BCAB, MURA, ANVS, ELEV, EQ, CMMB, LSTA, BFRG, LPCN, and EDSAShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include BioAtla (BCAB), Mural Oncology (MURA), Annovis Bio (ANVS), Elevation Oncology (ELEV), Equillium (EQ), Chemomab Therapeutics (CMMB), Lisata Therapeutics (LSTA), Bullfrog AI (BFRG), Lipocine (LPCN), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. BioAtla Mural Oncology Annovis Bio Elevation Oncology Equillium Chemomab Therapeutics Lisata Therapeutics Bullfrog AI Lipocine Edesa Biotech China Pharma (NYSE:CPHI) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Is CPHI or BCAB more profitable? BioAtla has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% BioAtla N/A -187.30%-96.33% Which has more volatility & risk, CPHI or BCAB? China Pharma has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Does the media favor CPHI or BCAB? In the previous week, China Pharma had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for BioAtla. China Pharma's average media sentiment score of 0.17 beat BioAtla's score of 0.00 indicating that China Pharma is being referred to more favorably in the media. Company Overall Sentiment China Pharma Neutral BioAtla Neutral Which has better valuation & earnings, CPHI or BCAB? China Pharma has higher earnings, but lower revenue than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.53M10.78-$3.08MN/AN/ABioAtla$11M1.72-$123.46M-$1.44-0.22 Does the MarketBeat Community believe in CPHI or BCAB? BioAtla received 25 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 65.79% of users gave BioAtla an outperform vote while only 0.00% of users gave China Pharma an outperform vote. CompanyUnderperformOutperformChina PharmaOutperform VotesNo VotesUnderperform Votes91100.00% BioAtlaOutperform Votes2565.79% Underperform Votes1334.21% Do analysts recommend CPHI or BCAB? BioAtla has a consensus price target of $6.00, indicating a potential upside of 1,753.00%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than China Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders hold more shares of CPHI or BCAB? 77.2% of BioAtla shares are held by institutional investors. 17.3% of China Pharma shares are held by company insiders. Comparatively, 11.5% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryBioAtla beats China Pharma on 9 of the 16 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$48.82M$6.44B$5.31B$18.41BDividend YieldN/A3.20%5.45%4.19%P/E RatioN/A6.8921.8831.09Price / Sales10.78230.51380.6626.55Price / CashN/A65.6738.2617.53Price / Book2.145.936.454.30Net Income-$3.08M$142.99M$3.22B$1.02B1 Month Performance-94.67%-13.56%-9.75%-8.21%1 Year Performance-95.29%-8.89%11.50%1.69% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina PharmaN/A$1.50-4.1%N/A-95.3%$4.88M$4.53M0.00250Analyst ForecastNews CoverageHigh Trading VolumeBCABBioAtla1.9505 of 5 stars$0.32+4.2%$6.00+1,802.9%-84.6%$18.41M$11M-0.1960Positive NewsGap UpMURAMural Oncology2.5875 of 5 stars$1.03flat$13.00+1,162.1%-24.4%$17.75MN/A-0.11119Options VolumeGap UpANVSAnnovis Bio1.4763 of 5 stars$1.24-5.0%$37.00+2,896.0%-87.7%$17.58MN/A-0.283Gap UpELEVElevation Oncology3.0594 of 5 stars$0.29+4.9%$3.39+1,052.4%-89.8%$17.40MN/A-0.3640News CoverageGap UpEQEquillium3.0517 of 5 stars$0.49+1.5%$3.00+516.9%-70.7%$17.32M$41.10M-3.4740Short Interest ↓Positive NewsGap UpCMMBChemomab Therapeutics2.851 of 5 stars$1.18+10.7%$9.00+662.4%+64.7%$16.95MN/A-1.1820Positive NewsGap UpLSTALisata Therapeutics2.003 of 5 stars$1.96+0.5%$15.00+665.3%-16.3%$16.90M$1M-0.7830News CoveragePositive NewsBFRGBullfrog AI0.6095 of 5 stars$1.79-14.8%N/A-38.5%$16.85M$60,000.00-2.114Short Interest ↑News CoverageHigh Trading VolumeLPCNLipocine2.6388 of 5 stars$3.12+1.6%$10.00+220.5%-43.1%$16.69M$11.20M-4.1110Analyst ForecastEDSAEdesa Biotech3.1982 of 5 stars$2.38+5.8%$21.00+782.4%-49.2%$16.64MN/A-1.2720Short Interest ↓Positive NewsGap Down Related Companies and Tools Related Companies BioAtla Competitors Mural Oncology Competitors Annovis Bio Competitors Elevation Oncology Competitors Equillium Competitors Chemomab Therapeutics Competitors Lisata Therapeutics Competitors Bullfrog AI Competitors Lipocine Competitors Edesa Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
